Design, Synthesis and Structure of Peptides and Proteins news

<p>Salvador Guardiol holds a  “la Caixa/Severo Ochoa” scholarship from 2013</p>
11 Mar 2016

“I’m still enthusiastic. Just a bit less naïve.” Salva Guardiola, PhD student in Ernest Giralt’s Design, Synthesis, and Structure of Peptide and Proteins Lab, has just published his first paper in ChemBioChem. And in the life of a researcher, the first article is never forgotten, it leaves a mark the rest of your career.

The idea Salva and his colleagues had was to design and test a peptide,...

5 Feb 2016

The medical portal ""El Médico Hospitaliario" and other media report on IRB Barcelona's research on compounds able to act against EGF, a little-explored cancer target.
The study has been published in ChemBioChem.

Link to La Vanguardia

Link to...

<p>The compound Cp28 (orange) binds to the EGF protein (green), a target in cancer. This interaction prevents EGF from binding to its receptor EGFR.</p>
3 Feb 2016

The molecules synthesized by Ernest Giralt’s lab at IRB Barcelona bind a key protein in cancer that has received little attention as a therapeutic target.

The long-term goal is to provide a new chemotherapy treatment.

<p>Laura Nevola</p>
27 Jan 2016

After seven intense years in Ernest Giralt’s lab, Laura Nevola (Benevento, Italy, 1980) is ready to undertake a new challenge in her career. “It’s time to fly on my own,” she says.

18 Dec 2015

This award recognizes his thesis, which addressed the use of shuttle peptides to overcome the blood-brain barrier.

27 Nov 2015

Professor Ernest Giralt talks about the blood-brain barrier on the blog Activa tu Neurona. In the podcast, he explains how this barrier works and also draws an analogy between the work done at his lab and a famous fairy tale, which illustrates his research.

4 Nov 2015

La Vanguardia, Diario Médico and many other media, up to 100,  have reported on the Blood-Brain Barrier congress held in Barcelona and organised by IRB Barcelona and the BBVA Foundation.

Link to La Vanguardia

<p>Detail of one millimeter of a mouse brain. In green, capillaries that form part of the blood-brain barrier; in red, molecules attached to the shuttle patented by IRB Barcelona have managed to cross the barrier and reach the brain. (B Oller, IRB)</p>
2 Nov 2015

It has been known for 100 years that the brain is protected by thousands of tight capillaries that form a barrier—a defence mechanism but also an obstacle to the use of promising drugs to treat diseases affecting the central nervous system.

Ernest Giralt: “This barrier is responsible for the low success rate of new drugs to enter the brain. We now have the strategies to overcome it.”

20 pioneering scientists present their latest research on the barrier and the breakthroughs in therapeutic shuttle transporters that target the brain in the Blood-Brain-Barrier Conference, an event organised by IRB Barcelona and supported by the BBVA Foundation.

One of the latest results is a shuttle based on bee venom developed at IRB Barcelona.

16 Oct 2015

The medical newspaper Diario Médico has echoed on   the research performed by Natàlia Carulla's group that has recently been published in Scientific Reports, a journal that belongs to the Nature group. The study offers data that challenge current views about the number and the shape of the first aggregates formed by amyloid beta protein, a molecule related to Alzheimer's...

<p>Globular shape that initial aggregates of amyloid beta protein adopt (Image: A. Arcella, IRB Barcelona)</p>
14 Oct 2015

Natàlia Carulla’s research group provides information that questions the widely accepted premise regarding the number of molecules and the shape of the first aggregates formed by amyloid beta protein

Amyloid beta protein aggregation, the process by which molecules of this protein adhere to each other is strongly associated with the development of Alzheimer’s disease

Carulla’s work ultimately seeks to identify molecules that interfere with the initial stages of aggregation as a strategy to combat the disease.